FDA Approves Kamada's New In-House Rabies Testing Lab, Boosting Key Product Efficiency
KMDA sits 23% above its 52-week low of $6.5.
Summary
The FDA has approved Kamada's new in-house Rabies Virus Neutralization Testing Laboratory, which will perform critical RFFIT tests for the manufacturing of KEDRAB and KAMRAB. This follows a 6-K filing on the same day and a prior FDA approval for a new plasma collection center in March. KEDRAB and KAMRAB generated over $70 million in sales in 2025, representing the company's leading product franchise. The new lab enhances operational efficiencies, strengthens quality control, and improves vertical integration for these key revenue drivers.
At the time of this announcement, KMDA was trading at $7.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $450.5M. The 52-week trading range was $6.50 to $9.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.